Modern aspects of complex therapy for recurrent genital herpes

Abstract

Incidence of reported cases of genital herpes in different countries has increased dramatically during the last years, which is essentially caused by spread of asymptomatic or atypical types of herpes. Frequent relapses of herpes infection are characterized by changes in the immunological status. The authors of presented article analysed the findings of foreign and domestic studies on the treatment of the disease, systematized information about the features of antiviral chemotherapy drugs used in the treat-ment of genital herpes, identified criteria for the efficacy and duration of suppressive therapy, and the feasibility of its combination with courses of immunomodulatory drugs. The article summarizes the authors’ own experience in the treatment of genital herpes in 50 patients, who were randomly divided into 2 groups: (active treatment) group 1 consisted of 25 women who received antiviral (acyclovir and its analogues) and immunomodulatory therapy (aminodihydrophthalasindione sodium, suppositories), (comparison) group 2 consisted of 25 patients who received antiviral therapy only. The following were criteria for the inclusion of patients: genital herpes history, clinical presentation of genital herpes during the prodromal period or exacerbation, and no more than 48 hours after the rash occurred.The results of evaluation of the treatment effectiveness showed that the vesicles disappeared and the crusts formed during aminodihydrophthalasindione sodium therapy in the active treatment group of patients as early as Day 2-5 after starting treatment, while the acute phase of local inflammation in the comparison group was reversed only by Day 4-5. Complete reepitheli-alization occurred in the active treatment and comparison groups by Day 6-7 of the treatment. At the same time, the PCR test did not detect HSV-2 in smears in 24 (96.0%) women in the active treatment group and in 25 (88.0%) women in the comparison group. No one had any fresh rashes in the course of treatment with the drug. In addition, the authors reported prolongation of clinical remission in the active treatment group up to 5 months (up to 55 days on average).As can be seen from the above, the inclusion of immunomodulatory drugs in the combination specific antiviral therapy leads to faster achievement of the clinical effect, allows to reduce frequency of relapses and improves the patients’ quality of life.

Keywords

• genital herpes
• recurrent
• complex therapy
• immunomodulators
• aminodihydrophthalasindione sodium